Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meningococcal A, C, Y and W-135 conjugate vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal A, C, Y and W‑135 conjugate vaccines are injectable biologic vaccines indicated for active immunization to prevent invasive disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W‑135. These vaccines work by stimulating the immune system to produce antibodies against the polysaccharide capsules of these four serogroups, using a protein carrier (such as diphtheria toxoid or CRM197) to enhance immunogenicity. They are primarily used in children, adolescents, and adults at risk for meningococcal disease. The main developers include Novartis (now part of GSK), GSK itself, and Tianjin CanSino Biotechnology. The primary indication is prevention of invasive meningococcal infections[2][4][6][7].
- Brand names
- MenveoMenactraMenhycia
- Other names
- meningococcal ACWY vaccinequadrivalent A C Y W-135 meningococcal vaccinemultivalent ACWY vaccine candidate - Novartis
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on Meningococcal A, C, Y and W-135 conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meningococcal A, C, Y and W-135 conjugate vaccine.